[go: up one dir, main page]

AR093226A1 - Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales - Google Patents

Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales

Info

Publication number
AR093226A1
AR093226A1 ARP130102562A ARP130102562A AR093226A1 AR 093226 A1 AR093226 A1 AR 093226A1 AR P130102562 A ARP130102562 A AR P130102562A AR P130102562 A ARP130102562 A AR P130102562A AR 093226 A1 AR093226 A1 AR 093226A1
Authority
AR
Argentina
Prior art keywords
etilureido
tetrahidrofuran
pirimidin
ilo
propan
Prior art date
Application number
ARP130102562A
Other languages
English (en)
Inventor
Odowd Hardwin
Macikenas Dainius
Song Bin
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AR093226A1 publication Critical patent/AR093226A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

También provee composiciones farmacéuticamente aceptables que comprenden la forma sólida del compuesto y un método para utilizar las composiciones en el tratamiento de varios trastornos. Reivindicación 1: Un compuesto sólido de la fórmula (1) caracterizado porque X es -PO(OH)₂, -PO(OH)O⁻M⁺, o -PO(O⁻)₂·2M⁺, donde M es un catión monovalente.
ARP130102562A 2012-07-18 2013-07-18 Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales AR093226A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261673104P 2012-07-18 2012-07-18

Publications (1)

Publication Number Publication Date
AR093226A1 true AR093226A1 (es) 2015-05-27

Family

ID=48874568

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102562A AR093226A1 (es) 2012-07-18 2013-07-18 Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales

Country Status (4)

Country Link
US (1) US9018216B2 (es)
AR (1) AR093226A1 (es)
TW (1) TWI595002B (es)
WO (1) WO2014015105A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG191946A1 (en) * 2011-01-14 2013-08-30 Vertex Pharma Pyrimidine gyrase and topoisomerase iv inhibitors
WO2012097270A1 (en) * 2011-01-14 2012-07-19 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea
CA2824519C (en) * 2011-01-14 2020-06-16 Vertex Pharmaceuticals Incorporated Process of making gyrase and topoisomerase inhibitors
TWI535714B (zh) * 2011-01-14 2016-06-01 維泰克斯製藥公司 旋轉酶抑制劑（ｒ）－１－乙基－３－［６－氟－５－［２－（１－羥基－１－甲基－乙基）嘧啶－５－基］－７－（四氫呋喃－２－基）－１ｈ－苯并咪唑－２－基］脲之固體形式
EP2721026B1 (en) * 2011-06-20 2016-03-02 Vertex Pharmaceuticals Incorporated Phosphate esters of gyrase and topoisomerase inhibitors
AR093226A1 (es) 2012-07-18 2015-05-27 Vertex Pharma Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
WO2015114452A2 (en) 2014-02-03 2015-08-06 Biota Europe Ltd Antibacterial compounds
JP2024537582A (ja) * 2021-10-26 2024-10-15 スペロ セラピューティックス，インコーポレイテッド Ｓｐｒ７２０のヒト有効用量及び投与スケジュール
AU2022399569A1 (en) * 2021-11-30 2024-06-06 Mannkind Corporation Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2015676A1 (de) 1970-04-02 1971-10-21 Farbenfabriken Bayer Ag, 5090 Leverkusen Neue Imine der 2-Formyl-chinoxalindi-N-oxidcarbon-säure-(3) und deren Salze, Verfahren zu ihrer Herstellung und ihre Verwendung als antimikrobielle Mittel
US4174400A (en) 1978-09-13 1979-11-13 Merck & Co., Inc. Anthelmintic benzimidazoles
US4512998A (en) 1980-10-20 1985-04-23 Schering Corporation Anthelmintic benzimidazole carbamates
CA2028530A1 (en) 1989-11-21 1991-05-22 Christian Hubschwerlen Substituted pyrimidobenzimidazole derivatives
WO1995008344A1 (en) 1993-09-22 1995-03-30 Xoma Corporation Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic
CA2181164C (en) 1994-01-14 2008-01-08 Arnold Horwitz Anti-gram-positive bacterial methods and materials
DE19514313A1 (de) 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
US5643935A (en) 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
TW538046B (en) 1998-01-08 2003-06-21 Hoechst Marion Roussel Inc Aromatic amides having antiobiotic activities and the preparation processes, intermediates and pharmaceutical composition thereof
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
GB9911594D0 (en) 1999-05-19 1999-07-21 Smithkline Beecham Plc Novel compounds
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US7419678B2 (en) 2000-05-12 2008-09-02 Cordis Corporation Coated medical devices for the prevention and treatment of vascular disease
US20040018228A1 (en) 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
EP1341769B1 (en) 2000-12-15 2007-10-17 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
US20030229390A1 (en) 2001-09-17 2003-12-11 Control Delivery Systems, Inc. On-stent delivery of pyrimidines and purine analogs
KR20040051618A (ko) 2001-10-25 2004-06-18 위스콘신 얼럼나이 리서어치 화운데이션 단백질 티로신 키나아제 저해제로 피복되거나 함침된 혈관스텐트 또는 이식물 및 그를 사용하는 방법
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20030204168A1 (en) 2002-04-30 2003-10-30 Gjalt Bosma Coated vascular devices
US7727992B2 (en) 2002-06-13 2010-06-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7618974B2 (en) 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8404852B2 (en) 2003-01-31 2013-03-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7582641B2 (en) 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8193352B2 (en) 2003-01-31 2012-06-05 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) * 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US7569591B2 (en) 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
EP1948635A1 (en) 2005-11-07 2008-07-30 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
GB0724349D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
RU2469034C2 (ru) 2006-12-04 2012-12-10 Астразенека Аб Химические соединения
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
EP2321309A1 (en) 2008-06-25 2011-05-18 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents
EP2475666A2 (en) 2009-09-11 2012-07-18 Trius Therapeutics, Inc. Gyrase inhibitors
CN102725274A (zh) 2009-10-16 2012-10-10 Rib-X制药公司 抗微生物化合物和其制备和使用方法
CN103249732B (zh) 2010-10-08 2016-08-10 生物区欧洲有限公司 抑制2-乙基氨甲酰氨基-1,3-苯并噻唑-5-基的细菌拓扑异构酶ii
SG191946A1 (en) 2011-01-14 2013-08-30 Vertex Pharma Pyrimidine gyrase and topoisomerase iv inhibitors
TWI535714B (zh) 2011-01-14 2016-06-01 維泰克斯製藥公司 旋轉酶抑制劑（ｒ）－１－乙基－３－［６－氟－５－［２－（１－羥基－１－甲基－乙基）嘧啶－５－基］－７－（四氫呋喃－２－基）－１ｈ－苯并咪唑－２－基］脲之固體形式
CA2824519C (en) * 2011-01-14 2020-06-16 Vertex Pharmaceuticals Incorporated Process of making gyrase and topoisomerase inhibitors
WO2012097270A1 (en) 2011-01-14 2012-07-19 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea
EP2721026B1 (en) * 2011-06-20 2016-03-02 Vertex Pharmaceuticals Incorporated Phosphate esters of gyrase and topoisomerase inhibitors
JP2015514063A (ja) 2012-03-22 2015-05-18 ビオタ ヨーロッパ リミテッドＢｉｏｔａ Ｅｕｒｏｐｅ Ｌｔｄ 抗菌化合物
AR093226A1 (es) 2012-07-18 2015-05-27 Vertex Pharma Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases

Also Published As

Publication number Publication date
TW201408681A (zh) 2014-03-01
WO2014015105A1 (en) 2014-01-23
US20140031318A1 (en) 2014-01-30
TWI595002B (zh) 2017-08-11
US9018216B2 (en) 2015-04-28

Similar Documents

Publication Publication Date Title
AR093226A1 (es) Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
GEAP202015005A (en) Diacylglycerol acyltransferase 2 inhibitors
MX2013005292A (es) Sal (es) de dimetil-amida del acido 7-ciclopentil-2- (5-piperazin-1-il-piridin-2-il-amino) -7h-pirrolo- [2, 3-d]-pirimidin-6-carboxilico y procesos para su elaboracion.
BR112015022197A2 (pt) tratamento de cataplexia
CL2016000241A1 (es) Formulación de inhibidores de la syk.
NZ702414A (en) Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions
PH12014502733A1 (en) Neprilysin inhibitors
MX2015016971A (es) Formulacion que comprende un agente hipolipidemico.
UY34811A (es) Compuestos y composiciones para inhibir la actividad de la abl1, abl2 y bcr-abl1
ECSP14013329A (es) Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas
MD20160099A2 (ro) Inhibitori ai diacilglicerol aciltransferazei 2 pentru utilizare în tratamentul tulburărilor metabolice şi a celor asociate
MY176246A (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
EA201591628A1 (ru) Дейтерированный палбоциклиб
FR3012725B1 (fr) Compositions d'agents de lutte biologique, leur procede de preparation et leurs utilisations
DOP2014000178A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2
EA201790276A1 (ru) Новые имидазопиридазиновые соединения и их применение
UY34722A (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil] etil}amino)-1-hidroxietil]-8- hidroxiquinolin-2(1h)-ona
MX2016004841A (es) Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk).
BR112014000499A2 (pt) compostos de quinolona de aminometila
MX359556B (es) Acido 2-[5-[n-(4-fluorofenil)carbamoíl]pirimidin-2-ilsulfanilmetil ]-4-(trifluorometoxi)fenil]borónico.
GB2515440A (en) Vesicular formulations
EA201690797A1 (ru) Новые соединения

Legal Events

Date Code Title Description
FB Suspension of granting procedure